preemptive therapy, CD20 monoclonal antibody
Showing 1 - 25 of >10,000
PTLD, CAEBV, HLH Trial in Beijing (low-dose CD20 mAb injection)
Enrolling by invitation
- PTLD
- +2 more
- low-dose CD20 monoclonal antibody injection
-
Beijing, Beijing, ChinaBeijing Friendship Hospital
Feb 24, 2022
Primary Membranous Nephropathy Trial in Beijing (B007)
Not yet recruiting
- Primary Membranous Nephropathy
-
Beijing, ChinaPeking university first hospital
Dec 20, 2022
Primary Immune Thrombocytopenia (ITP) Trial in Tianjin (TPO-RAs, TPO-RAs combining anti-CD 20 mAb)
Not yet recruiting
- Primary Immune Thrombocytopenia (ITP)
- TPO-RAs
- TPO-RAs combining anti-CD 20 monoclonal antibody
-
Tianjin, ChinaInstitute of Hematology and Blood Diseases Hospital, Chinese Aca
Feb 7, 2023
Aplastic Anemia Trial in Suzhou (CD20 mAb, ATG)
Recruiting
- Aplastic Anemia
- CD20 monoclonal antibody
- ATG
-
Suzhou, Jiangsu, ChinaThe First Affiliated Hospital of Soochow University
Aug 21, 2022
B-cell Lymphoma Recurrent, B-cell Lymphoma Refractory Trial in China (Orelabrutinib, Recombinant humanized mAb MIL62 injection)
Active, not recruiting
- B-cell Lymphoma Recurrent
- B-cell Lymphoma Refractory
- Orelabrutinib
- Recombinant humanized monoclonal antibody MIL62 injection
-
Bengbu, Anhui, China
- +9 more
Nov 11, 2022
Lymphoma Trial (BYON4228 + Rituximab)
Not yet recruiting
- Lymphoma
- BYON4228 + Rituximab
- (no location specified)
Feb 20, 2023
Recurrent DLBCL, Recurrent Follicular Lymphoma, Refractory DLBCL Trial in Seattle (Laboratory Biomarker Analysis, Pembrolizumab,
Active, not recruiting
- Recurrent Diffuse Large B-Cell Lymphoma
- +3 more
- Laboratory Biomarker Analysis
- +3 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Jul 20, 2022
Nodular Lymphocyte Predominant Hodgkin Lymphoma, Recurrent Nodular Lymphocyte Predominant Hodgkin Lymphoma, Refractory Nodular
Not yet recruiting
- Nodular Lymphocyte Predominant Hodgkin Lymphoma
- +2 more
- Biopsy
- +9 more
- (no location specified)
Jun 1, 2023
CD20-positive Non-Hodgkin Lymphoma Trial in China (EX103 injection)
Recruiting
- CD20-positive Non-Hodgkin Lymphoma
- EX103 injection
-
Zhengzhou, Henan, China
- +3 more
Aug 28, 2023
Mantle Cell Lymphoma Trial in Duarte (drug, procedure, biological)
Not yet recruiting
- Mantle Cell Lymphoma
- Acalabrutinib
- +8 more
-
Duarte, CaliforniaCity of Hope Medical Center
Sep 20, 2023
Monomorphic B-Cell Post-Transplant Lymphoproliferative Disorder, Polymorphic Post-Transplant Lymphoproliferative Disorder Trial
Not yet recruiting
- Monomorphic B-Cell Post-Transplant Lymphoproliferative Disorder
- Polymorphic Post-Transplant Lymphoproliferative Disorder
- Biopsy
- +5 more
-
New Brunswick, New Jersey
- +2 more
Mar 23, 2023
B-cell Non-Hodgkins Lymphoma (B-NHL) Trial (Odronextamab, REGN5837)
Not yet recruiting
- B-cell Non-Hodgkins Lymphoma (B-NHL)
- (no location specified)
Jan 5, 2023
Blastoid Variant Mantle Cell Lymphoma, Mantle Cell Lymphoma, Pleomorphic Variant Mantle Cell Lymphoma Trial in Duarte
Not yet recruiting
- Blastoid Variant Mantle Cell Lymphoma
- +2 more
- Biopsy
- +8 more
-
Duarte, CaliforniaCity of Hope Medical Center
May 15, 2023
Chronic Lymphocytic Leukemia Trial in Portland (drug, procedure, biological, other)
Not yet recruiting
- Chronic Lymphocytic Leukemia
- Acalabrutinib
- +8 more
-
Portland, OregonOHSU Knight Cancer Institute
Jul 12, 2023
Ann Arbor Stage I Grade 1 Follicular Lymphoma, Ann Arbor Stage I Grade 2 Follicular Lymphoma, Ann Arbor Stage II Grade 1
Active, not recruiting
- Ann Arbor Stage I Grade 1 Follicular Lymphoma
- +3 more
- Clinical Observation
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Dec 5, 2022
DLBCL, Grade 3b Follicular Lymphoma, Primary Mediastinal (Thymic) Large B-Cell Lymphoma Trial (biological, procedure, drug,
Not yet recruiting
- Diffuse Large B-Cell Lymphoma
- +6 more
- Axicabtagene Ciloleucel
- +10 more
- (no location specified)
Jan 13, 2023
CD20 Positive B Cell Non-Hodgkin's Lymphoma Trial in Guangzhou, Tianjin (B001)
Completed
- CD20 Positive B Cell Non-Hodgkin's Lymphoma
- B001
-
Guangzhou, Guangdong, China
- +1 more
Nov 11, 2021
Grade 3a Follicular Lymphoma, Recurrent Follicular Lymphoma, Recurrent Grade 1 Follicular Lymphoma Trial in Houston (other,
Completed
- Grade 3a Follicular Lymphoma
- +9 more
- Laboratory Biomarker Analysis
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Jan 31, 2023
CD20-positive B-cell Non-Hodgkin Lymphoma Trial in Beijing (Recombinant anti-CD20 mAb-MMAE coupling agent for injection
Recruiting
- CD20-positive B-cell Non-Hodgkin Lymphoma
- Recombinant anti-CD20 monoclonal antibody-MMAE coupling agent for injection (TRS005)
-
Beijing, Beijing, ChinaChinese Academy of Medical Sciences, Cancer Hospital
May 24, 2022
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Columbus (Acalabrutinib, Obinutuzumab, Venetoclax)
Recruiting
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Acalabrutinib
- +2 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Nov 2, 2022
Immune Thrombocytopenia, Treatment Trial in Tianjin (Obinutuzumab Injection [Gazyva])
Not yet recruiting
- Immune Thrombocytopenia
- Treatment
- Obinutuzumab Injection [Gazyva]
-
Tianjin, ChinaChinese Academy of Medical Science and Blood Disease Hospital
Aug 9, 2023
Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia Trial in France, Germany, United States (Odronextamab multiple dose levels)
Recruiting
- Non-Hodgkin Lymphoma
- Chronic Lymphocytic Leukemia
- Odronextamab multiple dose levels
-
Orange, California
- +20 more
Dec 14, 2022
B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Recurrent B Acute
Recruiting
- B Acute Lymphoblastic Leukemia
- +2 more
- Dasatinib
- +4 more
-
Portland, OregonOHSU Knight Cancer Institute
Dec 16, 2022
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8 Trial in Los
Recruiting
- Anatomic Stage IV Breast Cancer AJCC v8
- +5 more
- Anti-CD40 Agonist Monoclonal Antibody CDX-1140
- +3 more
-
Los Angeles, CaliforniaUSC/Norris Comprehensive Cancer Center
Jan 31, 2023